assembly Bill A7979A

2017-2018 Legislative Session

Prohibits certain insurance policies from requiring prior authorization for certain medications used in the treatment of substance use disorders; repealer

download bill text pdf

Sponsored By

Archive: Last Bill Status - Passed Assembly


  • Introduced
  • In Committee
  • On Floor Calendar
    • Passed Senate
    • Passed Assembly
  • Delivered to Governor
  • Signed/Vetoed by Governor

Your Voice

do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

view actions (17)
Assembly Actions - Lowercase
Senate Actions - UPPERCASE
Mar 26, 2018 referred to insurance
delivered to senate
passed assembly
Jan 03, 2018 ordered to third reading cal.567
returned to assembly
died in senate
Jun 21, 2017 referred to rules
delivered to senate
passed assembly
Jun 20, 2017 ordered to third reading rules cal.617
rules report cal.617
reported
reported referred to rules
reported referred to codes
Jun 08, 2017 print number 7979a
Jun 08, 2017 amend and recommit to insurance
May 23, 2017 referred to insurance

A7979 - Details

See Senate Version of this Bill:
S6674
Current Committee:
Senate Insurance
Law Section:
Insurance Law
Laws Affected:
Amd §§3216, 3221 & 4303, rpld §3216 sub§ (i) ¶31-a, §3221 sub§ (l) ¶¶7-a & 7-b, §4303 sub§§ (l-1) & (l-2), Ins L
Versions Introduced in 2019-2020 Legislative Session:
A2904, S4808

A7979 - Summary

Prohibits certain insurance policies from requiring prior authorization for buprenorphine products, methadone and long acting injectable naltrexone for detoxification or maintenance treatment of substance use disorders.

A7979 - Bill Text download pdf


                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                  7979

                       2017-2018 Regular Sessions

                          I N  A S S E M B L Y

                              May 23, 2017
                               ___________

Introduced  by M. of A. QUART -- read once and referred to the Committee
  on Insurance

AN ACT to amend the insurance law, in relation  to  prohibiting  certain
  insurance  policies  from  requiring  prior  authorization for certain
  medications used in the treatment of substance use disorders;  and  to
  repeal certain provisions of such law relating thereto

  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section 1. Paragraph 31-a of subsection (i) of  section  3216  of  the
insurance  law  is REPEALED and a new paragraph 31-a is added to read as
follows:
  (31-A) (A) NO POLICY THAT PROVIDES MEDICAL, MAJOR MEDICAL  OR  SIMILAR
COMPREHENSIVE-TYPE COVERAGE AND PROVIDES COVERAGE FOR PRESCRIPTION DRUGS
FOR  MEDICATION  FOR  THE  TREATMENT  OF  A SUBSTANCE USE DISORDER SHALL
REQUIRE PRIOR AUTHORIZATION FOR AN INITIAL OR RENEWAL  PRESCRIPTION  FOR
ALL  BUPRENORPHINE  PRODUCTS  OR  LONG  ACTING INJECTABLE NALTREXONE FOR
DETOXIFICATION OR MAINTENANCE TREATMENT  OF  A  SUBSTANCE  USE  DISORDER
EXCEPT WHERE OTHERWISE PROHIBITED BY LAW.
  (B)  COVERAGE  PROVIDED  UNDER THIS PARAGRAPH MAY BE SUBJECT TO COPAY-
MENTS, COINSURANCE, AND ANNUAL  DEDUCTIBLES  THAT  ARE  CONSISTENT  WITH
THOSE IMPOSED ON OTHER BENEFITS WITHIN THE POLICY.
  §  2.  Paragraphs 7-a and 7-b of subsection (l) of section 3221 of the
insurance law are REPEALED and a new paragraph 7-a is added to  read  as
follows:
  (7-A) (A) EVERY POLICY THAT PROVIDES MEDICAL, MAJOR MEDICAL OR SIMILAR
COMPREHENSIVE-TYPE LARGE GROUP COVERAGE SHALL PROVIDE IMMEDIATE COVERAGE
FOR  ALL  BUPRENORPHINE  PRODUCTS  OR  LONG ACTING INJECTABLE NALTREXONE
WITHOUT PRIOR AUTHORIZATION FOR THE DETOXIFICATION OR MAINTENANCE TREAT-
MENT OF A SUBSTANCE USE DISORDER.

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD11793-01-7

Co-Sponsors

A7979A (ACTIVE) - Details

See Senate Version of this Bill:
S6674
Current Committee:
Senate Insurance
Law Section:
Insurance Law
Laws Affected:
Amd §§3216, 3221 & 4303, rpld §3216 sub§ (i) ¶31-a, §3221 sub§ (l) ¶¶7-a & 7-b, §4303 sub§§ (l-1) & (l-2), Ins L
Versions Introduced in 2019-2020 Legislative Session:
A2904, S4808

A7979A (ACTIVE) - Summary

Prohibits certain insurance policies from requiring prior authorization for buprenorphine products, methadone and long acting injectable naltrexone for detoxification or maintenance treatment of substance use disorders.

A7979A (ACTIVE) - Bill Text download pdf


                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                 7979--A

                       2017-2018 Regular Sessions

                          I N  A S S E M B L Y

                              May 23, 2017
                               ___________

Introduced  by M. of A. QUART -- read once and referred to the Committee
  on Insurance -- committee discharged, bill amended, ordered  reprinted
  as amended and recommitted to said committee

AN  ACT  to  amend the insurance law, in relation to prohibiting certain
  insurance policies from  requiring  prior  authorization  for  certain
  medications  used  in the treatment of substance use disorders; and to
  repeal certain provisions of such law relating thereto

  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section  1.  Paragraph  31-a  of subsection (i) of section 3216 of the
insurance law is REPEALED and a new paragraph 31-a is added to  read  as
follows:
  (31-A)  (A)  NO POLICY THAT PROVIDES MEDICAL, MAJOR MEDICAL OR SIMILAR
COMPREHENSIVE-TYPE COVERAGE AND PROVIDES COVERAGE FOR PRESCRIPTION DRUGS
FOR MEDICATION FOR THE TREATMENT  OF  A  SUBSTANCE  USE  DISORDER  SHALL
REQUIRE  PRIOR  AUTHORIZATION FOR AN INITIAL OR RENEWAL PRESCRIPTION FOR
ALL BUPRENORPHINE PRODUCTS, METHADONE OR LONG ACTING INJECTABLE NALTREX-
ONE FOR DETOXIFICATION OR  MAINTENANCE  TREATMENT  OF  A  SUBSTANCE  USE
DISORDER EXCEPT WHERE OTHERWISE PROHIBITED BY LAW.
  (B)  COVERAGE  PROVIDED  UNDER THIS PARAGRAPH MAY BE SUBJECT TO COPAY-
MENTS, COINSURANCE, AND ANNUAL  DEDUCTIBLES  THAT  ARE  CONSISTENT  WITH
THOSE IMPOSED ON OTHER BENEFITS WITHIN THE POLICY.
  §  2.  Paragraphs 7-a and 7-b of subsection (l) of section 3221 of the
insurance law are REPEALED and a new paragraph 7-a is added to  read  as
follows:
  (7-A) (A) EVERY POLICY THAT PROVIDES MEDICAL, MAJOR MEDICAL OR SIMILAR
COMPREHENSIVE-TYPE LARGE GROUP COVERAGE SHALL PROVIDE IMMEDIATE COVERAGE
FOR  ALL  BUPRENORPHINE  PRODUCTS,  METHADONE  OR LONG ACTING INJECTABLE
NALTREXONE WITHOUT PRIOR AUTHORIZATION FOR THE DETOXIFICATION OR MAINTE-
NANCE TREATMENT OF A SUBSTANCE USE DISORDER.

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD11793-02-7